President Donald Trump, accompanied by top health officials, announced sweeping changes to reduce prescription drug costs for Americans during a significant policy shift on Monday.

According to Breitbart, Trump signed an executive order in the Roosevelt Room aimed at lowering drug prices in the United States to match rates paid by other nations, potentially reducing costs by up to 90 percent.

The executive order represents a direct challenge to pharmaceutical companies' pricing practices. Health and Human Services Secretary Robert F. Kennedy, Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz, NIH Director Dr. Jay Bhattacharya, and FDA Commissioner Dr. Marty Makary stood alongside Trump during the announcement.

Trump administration targets unfair drug pricing practices

President Trump emphasized the disparity in pharmaceutical pricing between the United States and other countries. He explained that American consumers have been effectively subsidizing lower drug prices in foreign markets while pharmaceutical companies generate most of their profits domestically.

The White House fact sheet outlines specific measures to address these pricing inequities. Commerce Secretary Howard Lutnick and U.S. Trade Representative Jameson Greer will investigate foreign practices that artificially drive up American drug prices.

Trump shared his perspective on the current state of pharmaceutical pricing:

Starting today, the United States will no longer subsidize the health care of foreign countries, which is what we were doing. We were subsidizing others' health care–countries where they paid a small fraction for the same drug that what we pay many, many times more for, and we'll no longer tolerate profiteering and price gouging from Big Pharma.

Implementation of Most Favored Nation pricing system

The executive order establishes a framework for implementing "Most Favored Nation" pricing. This system will allow Americans to purchase medications directly from producers at internationally competitive rates.

The order grants Secretary Kennedy authority to take decisive action if pharmaceutical companies fail to comply with the new pricing guidelines. These measures include proposing rules to enforce most-favored-nation pricing and implementing additional strategies to reduce consumer costs.

Healthcare officials will communicate target prices to pharmaceutical manufacturers to secure optimal deals for American consumers. The administration expects this approach to yield significant savings for patients.

Strategic approach to pharmaceutical industry reform

The executive order addresses the disproportionate profit distribution in the pharmaceutical industry. Trump highlighted that while the United States represents only four percent of the world's population, it accounts for over two-thirds of pharmaceutical companies' profits.

Secretary Kennedy received broad authority to implement aggressive measures if manufacturers resist the pricing reforms. These powers include the ability to propose new regulations and take additional steps to combat anticompetitive practices.

The administration projects that these changes could result in price reductions ranging from 59 to 90 percent for many prescription medications. This represents one of the most significant reforms to pharmaceutical pricing in recent years.

Executive order reshapes American healthcare landscape

The Roosevelt Room executive order signing marked a pivotal moment in American healthcare policy. President Trump, supported by a team of prominent health officials including Secretary Kennedy, Dr. Oz, Dr. Bhattacharya, and Dr. Makary, introduced comprehensive measures to reform prescription drug pricing. The executive order directs Commerce Secretary Lutnick and Trade Representative Greer to investigate and address unfair international pricing practices while establishing a Most Favored Nation pricing system for American consumers. These changes aim to eliminate the disparity between domestic and international drug prices, potentially reducing costs by up to 90 percent for American patients.